Aurinia Pharmaceuticals Inc. (FRA:IKAP)

Market Cap	1.65B +60.6%
Revenue (ttm)	241.08M +20.4%
Net Income	244.61M +4,893.1%
EPS	1.76 +5,075.0%
Shares Out	n/a
PE Ratio	6.73
Forward PE	16.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	12.47
Previous Close	12.56
Day's Range	12.47 - 12.47
52-Week Range	6.19 - 14.27
Beta	n/a
RSI	53.29
Earnings Date	May 7, 2026

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 128
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IKAP

Financial Performance

In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.

Financial numbers in USD